The Pharmacy Times® HIV Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of HIV, a virus that attacks the body's immune system and, if left untreated, can lead to AIDS.
April 26th 2024
The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacist Credit)
2.0 Credits / HIV/AIDS
View More
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacy Technician Credi...
2.0 Credits / HIV/AIDS
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Treatment Decision-Making for Complex Patients With HIV: Drug Resistance, Adverse Effects, Comorbidities and Polypharmacy, and Overcoming Barriers to Equitable Care
1.5 Credits / HIV/AIDS
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Access, and Adherence
1.5 Credits / HIV/AIDS, Infectious Disease
View More
Report Cites Addressing Health Disparities to End HIV Epidemic
February 22nd 2021Researchers, advocates, and other stakeholders are urging for care to be expanded to overcome barriers in high-risk populations to address the HIV epidemic, as part of a series published in The Lancet HIV in the USA Series.
Read More
Impact of New Once-monthly, Long-acting HIV Regimen on Patient Care
February 17th 2021Pharmacy Times® interviewed Susan Swindells, MD, of the University of Nebraska Medical Center, on the impact of the recently FDA-approved once-monthly, long-acting HIV regimen on how providers care for patients with the virus.
Watch
Medicaid Expansion Helped Identify Undiagnosed HIV Infections, Increased Prevention Services
February 8th 2021In order to eradicate HIV, the researchers said increasing health coverage will be essential. Without that, HIV will continue to spread, and individuals will be unaware of their status.
Read More
FDA Approves Rilpivirine, Cabotegravir as the First Long-Acting Regimen for HIV Treatment
January 23rd 2021The FDA has approved cabenuva, which consists of rilpivirine and cabotegravir, for treating HIV-1 infection in adults. This therapy is the first once-monthly, long-acting injectable to be approved for the treatment of HIV.
Read More
Low Immunity Linked to Poor Outcomes in Patients with HIV, COVID-19
January 13th 2021As patients with HIV are living longer, they are also being diagnosed with chronic conditions that have become increasingly common in recent decades, putting them at higher risk of COVID-19 hospitalization and death.
Read More
The Importance of Conducting PrEP Counseling With a Sex Positive Approach
December 8th 2020At the virtual 2020 ASHP Midyear Clinical Meeting and Exhibition, Elyse Tung, PharmD, BCACP, discussed key counseling points for pharmacists to address with patients when prescribing and managing PrEP.
Read More